Full Press Release Details
Therapeutics Appoints Dr. Glenn Larsen to its Board of Directors
BEDFORD, Mass.--(BUSINESS WIRE)--February 19, 2015--Anika Therapeutics,
Inc. (Nasdaq: ANIK) today announced that it has appointed Glenn R.
Larsen, Ph.D., as a new independent member of its Board of Directors.
Dr. Larsen has extensive experience in the discovery, research and
development of biologics, small molecule therapeutics and drug delivery
medical devices for diverse clinical indications. Anika's Board of
Directors has voted to nominate Dr. Larsen for election by the
stockholders at the 2015 Annual Meeting.
"Glenn Larsen's more than 30 years of scientific and executive
management experience in pharmaceutical, biotech, orthopedics and
regenerative medicine will be a valuable asset to Anika and its board,"
said Charles H. Sherwood, Ph.D., president and chief executive officer.
"We are excited to welcome Glenn to the board and look forward to
benefiting from his strong technical expertise as well as his business
insight going forward."
Dr. Larsen, age 60, is Chief Executive Officer of Aquinnah
Pharmaceuticals, Inc., a pharmaceutical company focused on the
development of treatments for neurodegenerative diseases, which he
co-founded in February 2014. He also is a co-founder and Chairman of the
Board of Directors of 180 Therapeutics L.P., a clinical stage drug
delivery and development company founded in 2013. He previously served
as Chief Scientific Officer and Executive Vice President of Research and
Development at SpringLeaf Therapeutics, Inc., a producer of drug
delivery devices, and at Hydra Biosciences, Inc., a biopharmaceutical
company, as Chief Operating Officer, Executive Vice President of
Development, and a member of its board of directors. During his prior
employment at Wyeth/Genetics Institute, Dr. Larsen served in various
research and development leadership positions, including directing
Wyeth's second largest therapeutic area as Vice President
Musculoskeletal Sciences. Dr. Larsen received his Ph.D. in Biochemistry
from Stony Brook University.
About Anika Therapeutics, Inc.
Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops,
manufactures and commercializes therapeutic products for tissue
protection, healing and repair. These products are based on hyaluronic
acid (HA), a naturally occurring, biocompatible polymer found throughout
the body. Anika's products range from orthopedic/joint health solutions
led by Orthovisc and Monovisc ,
treatments for osteoarthritis of the knee, to surgical aids in the
anti-adhesion and ophthalmic fields. The Company also offers aesthetic
dermal fillers for the correction of facial wrinkles. Anika's Italian
subsidiary, Anika Therapeutics S.r.l., provides complementary HA
products in orthopedic/joint health and anti-adhesion, as well as
therapeutics in areas such as advanced wound treatment and ear, nose and
throat care. Its regenerative technology advances Anika's vision to
offer therapeutic products and medical solutions that go beyond pain
relief to protect and restore damaged tissue.
Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D.,
President and CEO, 781-457-9000
Sylvia Cheung, CFO, 781-457-9000